Teladoc Health (NYSE: TDOC) sank 74% last year -- and for one particular reason. The telemedicine giant reported two billion-dollar noncash goodwill impairment charges. Both were linked to the acquisition of chronic-care specialist Livongo.
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.